EDETEK Launches CONFORM™ – ONCO+, a Therapeutic Area-Specific Accelerator for the CONFORM™ Platform
Unveiling AI-Driven Accelerators to Enhance Clinical Trial Efficiency and Precision PRINCETON, N.J., Oct. 23, 2024 /PRNewswire/ -- EDETEK Inc., a...
Cancer
ACR Poker and Its Players Raise $20,000 for the United Breast Cancer Foundation
SAN JOSE, Costa Rica, Oct. 23, 2024 /PRNewswire/ -- In support of Breast Cancer Awareness Month, ACR Poker hosted its third...
MEDSIR takes part in the Nexus Conference to address the challenges and opportunities of geographic diversity in clinical trials
The conference, held in New Jersey, addresses critical aspects of clinical trials in the biopharmaceutical industry in the United States.Rui...
AngioDynamics and University College London Hospital Launch International Multi-Center Study to Assess Long Term Effects of Treatment with The NanoKnife® System
Investigator initiated trial seeks to validate safety, efficacy of the NanoKnife System in treating targeted tumors while reducing or delaying...
Kronos Bio Data Presentation at EORTC-NCI-AACR Symposium Highlights the Importance of p300 KAT Inhibition in HPV-Driven Tumors
– Preclinical data demonstrate that inhibiting the p300 KAT domain reactivates p53 in HPV-driven tumors resulting in anti-tumor activity –SAN...
Creative Innovation & Investment Shine On Day Two of Global Health Exhibition in Riyadh
World class exhibitors showcase opportunities and challenges posed by frontier-pushing digital and practical health technologies, set to revolutionize patient care...
Complete Blood Count Test with At-Home Sample Collection is Available for Direct-to-Patient Biopharma Programs through ixlayer’s ixEngage
ixEngage removes barriers to care by accelerating pre-treatment and routine CBC tests used for hundreds of conditions, including asthma, heart...
Lin Health to Collaborate with Mayo Clinic to Expand Access to Evidence-Based, Tech-Enabled Chronic Pain Care
Retraining the brain's neural circuitry through a behavioral health approach empowers people living with chronic pain to avoid costly and...
SOPHiA GENETICS to Announce Financial Results for Third Quarter 2024 on November 5, 2024
BOSTON and ROLLE, Switzerland, Oct. 22, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in...
NanoViricides President Dr. Diwan to Present at the PODD Conference
SHELTON, CT / ACCESSWIRE / October 22, 2024 / NanoViricides, Inc. (NYSE Amer.: NNVC ) (the "Company"), a clinical stage...
Autonomix Announces Reverse Stock Split
THE WOODLANDS, TX, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical...
Florida Oncology and Hematology and American Oncology Network Opens New Location in Cape Coral, Welcomes Medical Director, Dr. Van den Bergh, and Drs. Venkata Parsa, and Shivtaj Mann
Board-certified medical oncologists Magali Van den Bergh, MD, Venkata Parsa, MD, and Shivtaj Mann, DO join the Cape Coral physician...
Allarity Therapeutics to be Granted European Patent for DRP® Companion Diagnostic for Stenoparib
European Patent Office to grant a patent for DRP® companion diagnostic for Allarity’s stenoparib cancer therapy Patent applications for the...
Monopar Presents Encouraging Human Clinical Dosimetry Data on its uPAR Program at EANM 2024
WILMETTE, Ill., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharmaceutical company focused on developing innovative...
PDS Biotech Announces Presentation of Rationale and Design of First Recurrent Prostate Cancer Trial to Combine an Androgen Receptor Pathway Inhibitor with an Immunocytokine
Study to evaluate PDS01ADC + Xtandi® (Enzalutamide) versus Xtandi® alone to be presented by Dr. Ravi Madan, National Cancer Institute...
Indaptus Therapeutics Announces Clinical Supply Agreement with BeiGene to Evaluate Novel Cancer Treatment Combinations
Planned industry first clinical trial combining BeiGene's checkpoint inhibitor tislelizumab with Indaptus’ broadly targeted, short duration systemic immune stimulator Decoy20...
Aligos Therapeutics Announces U.S. FDA Clearance of IND Application for ALG-000184
Company to conduct a Phase 1 Drug-Drug Interaction StudyPhase 2 filing on track for Q1 2025 SOUTH SAN FRANCISCO, Calif.,...
ProPhase Labs to Present at the 2024 ThinkEquity Conference
GARDEN CITY, NY, Oct. 22, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (the “Company” or “ProPhase”), a next...
BriaCell Reports Outperforming Metastatic Breast Cancer Patients and Standard-Beating Survival Data
55% of BriaCell patients1 remained alive one year since enrollment in BriaCell’s Phase 2 study, markedly exceeding the survival rate...
SpringWorks Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
STAMFORD, Conn., Oct. 22, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe...